Ornithine Transcarbamylase Deficiency

Liver Disease in Urea Cycle Disorders

An Open-label Study to Investigate ECUR-506 in Male Babies Less Than 9 Months of Age With Neonatal Onset OTC Deficiency

Study for Adolescents and Adults With Ornithine Transcarbamylase Deficiency to Evaluate Safety and Tolerability of ARCT-810

Baby Detect : Genomic Newborn Screening

Hepatic Histopathology in Urea Cycle Disorders

Early Check: Expanded Screening in Newborns

A Study to Evaluate the Pharmacodynamics and Safety of ARCT-810 in Participants With OTCD

Long-term Follow-up (LTFU) Study of Participants in Any iECURE Protocol Using an Investigational Product (IP)

Phase 1b Study to Assess Safety, Tolerability, and Pharmacokinetics of ARCT-810 in Stable Adult Subjects With Ornithine Transcarbamylase Deficiency

Investigation of Brain Nitrogen in Partial Ornithine Transcarbamylase Deficiency (OTCD) Using 1 H MRS, DTI, and fMRI

Safety, Tolerability and Pharmacokinetics of ARCT-810 in Healthy Adult Subjects

Halting Ornithine Transcarbamylase Deficiency With Recombinant AAV in ChildrEn

Selective Screening of Children for Hereditary Metabolic Diseases by Tandem Mass Spectrometry in Kazakhstan

Adeno-Associated Virus (AAV) Antibody Study in Subjects OTC Deficiency, GSDIa, and Wilson Disease

Study to Characterize Rate of Ureagenesis in Patients With Ornithine Transcarbamylase (OTC) Deficiency

A Study to Assess Plasma Ammonia Time-Normalized Area Under the Curve and Rate of Ureagenesis in Healthy Adult Subjects

Safety, Tolerability and PK/PD Evaluation of Intravenous Administration of MRT5201 in Patients With OTC Deficiency

Human Heterologous Liver Cells for Infusion in Children With Urea Cycle Disorders

Neurologic Injuries in Adults With Urea Cycle Disorders